More or Less

We are vastly short of skilled security people. Therefore, we will never have more than we do now and those we have will never again make as much money as now they do.

[1]  Gene D Morse,et al.  Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. , 2003, The New England journal of medicine.

[2]  S. Hammer,et al.  Predictors of Virologic and Clinical Outcomes in HIV-1Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320 , 2001, Annals of Internal Medicine.

[3]  S. Hammer,et al.  A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. , 2003, The Journal of infectious diseases.

[4]  S. Hammer,et al.  HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  D. Bangsberg,et al.  Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. , 2004, The Journal of antimicrobial chemotherapy.

[6]  Douglas Richman,et al.  Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies , 1996, Annals of Internal Medicine.

[7]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[8]  S. Hammer,et al.  Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. , 2001, The New England journal of medicine.

[9]  Christopher D Pilcher,et al.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.

[10]  Victor DeGruttola,et al.  Assessing resistance costs of antiretroviral therapies via measures of future drug options. , 2003, The Journal of infectious diseases.